Epidemiology of Rhodotorula: An Emerging Pathogen

Table 1

Summary of reports of Rhodotorula fungemia (2000–2011).

Reference	Number of described cases	Species	Underlying disease
[46]	7	R. mucilaginosa	Hematological-solid malignancies
[52]	10	R.mucilaginosa	SBD; LT; AIDS
		R.glutinis
[48]	25	R. mucilaginosa	Hematological-solid malignancies; LC; SCA; SBD; CLD
[53]	2	R. glutinis/R. mucilaginosa	Lymphoma; solid tumor
[54]	1	R. mucilaginosa	Lymphoma
[55]	1	R. mucilaginosa	Lymphoma
[56]	2	R. mucilaginosa	Acute myeloid leukemia
[57]	1	R. glutinis	Nasopharyngeal carcinoma
[58]	1	R. mucilaginosa	SBD
[59]	3	Rhodotorula spp.	Hematological-solid malignancies
[60]	4	R. mucilaginosa	Prematurity
[61]	1	R. mucilaginosa	Acute myeloid leukemia
[62]	1	R. mucilaginosa	SCA
[63]	2	R. glutinis	Broad spectrum antibiotics
[64]	1	R. glutinis	Systemic lupus erythematous
[65]	1	R. glutinis	Solid organ transplant
[66]	1	R. glutinis	Liver cirrhosis
[67]	1	R. glutinis	Acute lymphoid leukemia
[68]	1	R. mucilaginosa	MS/BMT
[69]	1	R. mucilaginosa	Multiple abdominal surgeries; ovarian cancer; bowel necrosis

BMT: bone marrow transplant; CLD: congenital liver disease; LC: liver cirrhosis; LT: lung transplant; MS: myelodysplastic syndrome; SBD: short bowel disease; SCA: sickle cell anemia; SOT: solid organ transplant.